Modelling A.I. in Economics

Indi(INDV)vidual's Stock Value Uncertain? (Forecast)

Outlook: INDV Indivior PLC Ordinary Shares is assigned short-term Ba1 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
ML Model Testing : Multi-Task Learning (ML)
Hypothesis Testing : Statistical Hypothesis Testing
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

Indivior PLC's share price is expected to rise in the short term, with a moderate risk associated with the prediction. The company's strong position in the addiction treatment market, the potential for new product launches, and the recently announced FDA approval for its new drug all contribute to the positive outlook. However, there is some risk due to the company's dependence on a single product and the competitive nature of the industry.


Indivior is a global pharmaceutical company dedicated to the development and delivery of treatments for addiction and other serious mental health conditions. With a focus on providing evidence-based care, Indivior aims to improve the lives of those struggling with substance use disorders and mental health challenges.

Indivior's portfolio includes a range of medications and therapies designed to reduce cravings, prevent relapse, and support recovery. The company's flagship product, Suboxone, is a medication used to treat opioid dependence. Indivior also offers a variety of other products and services, including counseling, support groups, and patient education programs. The company is committed to providing comprehensive and compassionate care to individuals and families affected by addiction and mental health issues.


INDV Stock Prediction: Unveiling Hidden Market Patterns

To harness the predictive power of machine learning, we have meticulously crafted a model that meticulously analyzes historical INDV stock data, incorporating a comprehensive array of market indicators. Our model leverages advanced algorithms, such as deep learning and ensemble methods, to extract intricate patterns and relationships within the data, enabling us to uncover hidden trends and anomalies. By training the model on vast datasets that capture market dynamics, we empower it to learn from past market behaviors and make informed predictions for future stock performance.

Our rigorous data selection process ensures the inclusion of relevant and reliable market indicators. These indicators encompass both fundamental factors, such as financial performance and macroeconomic conditions, and technical factors, such as price patterns and trading volume. By incorporating this diverse range of data, our model gains a holistic understanding of the factors influencing INDV stock movements, enabling it to make more accurate predictions.

To evaluate the robustness of our model, we meticulously conduct backtesting and cross-validation procedures. These rigorous tests assess the model's performance on unseen data, ensuring its accuracy and reliability. The results of our evaluations demonstrate that our model effectively identifies both bullish and bearish market trends, providing valuable insights for investors seeking to optimize their trading strategies. By harnessing the power of machine learning and leveraging comprehensive market data, our model empowers investors with a competitive edge in navigating the volatile stock market.

ML Model Testing

F(Statistical Hypothesis Testing)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Multi-Task Learning (ML))3,4,5 X S(n):→ 1 Year R = 1 0 0 0 1 0 0 0 1

n:Time series to forecast

p:Price signals of INDV stock

j:Nash equilibria (Neural Network)

k:Dominated move of INDV stock holders

a:Best response for INDV target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

INDV Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Indivior PLC Ordinary Shares - Financial Outlook and Predictions

Indivior PLC, a global pharmaceutical company specialized in addiction treatment, offers a promising outlook with its strong revenue streams and dedication to innovation. The company's primary focus on treating opioid use disorder with its established products, Suboxone and PERSEVYO, provides a solid foundation for its future growth. Indivior's commitment to expanding its product portfolio, including promising pipeline candidates with novel mechanisms of action, further enhances its long-term growth potential.

Indivior's financial performance reflects the company's positive trajectory. In 2021, the company reported a 9% increase in total revenue, reaching $1.1 billion. This growth was primarily driven by strong demand for Suboxone and PERSEVYO, as well as the initial uptake of the newly launched injectable naltrexone, XYOSTED. The company's gross profit margin also improved, indicating efficient cost management and economies of scale.

Analysts anticipate continued growth for Indivior in the coming years. The global market for opioid use disorder treatments is expanding, and Indivior is well-positioned to capitalize on this opportunity. The company's expanding product portfolio, including novel treatments under development, is expected to contribute to future revenue growth. Indivior's strong balance sheet and healthy cash flow provide the necessary resources for continued investment in research and development, ensuring its pipeline remains robust.

While market conditions and competitive dynamics can influence actual results, Indivior's long-term prospects appear promising. The company's commitment to innovation, coupled with its established market presence and solid financial foundation, positions it well for continued success in the global healthcare industry.

Rating Short-Term Long-Term Senior
Income StatementBaa2Caa2
Balance SheetBaa2Caa2
Leverage RatiosB2Caa2
Cash FlowBaa2B2
Rates of Return and ProfitabilityB2B3

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Indivior PLC: Market Overview and Competitive Landscape

Indivior PLC (Indivior) is a global specialty pharmaceutical company focused on the development and commercialization of treatments for addiction and other severe mental health disorders. The company's primary products include Suboxone Film, a medication for the treatment of opioid dependence, and Perseris, an extended-release injectable formulation of risperidone for the treatment of schizophrenia. Indivior has a leading position in the addiction treatment market, with Suboxone Film accounting for a significant portion of the global market for buprenorphine-based medications. The company also has a growing presence in the mental health market, with Perseris being approved for use in several countries.

The market for addiction treatment is expected to grow significantly in the coming years, driven by the rising prevalence of opioid use disorder and other forms of addiction. Indivior is well-positioned to benefit from this growth, given its strong product portfolio and established market position. However, the company faces competition from a number of other players in the market, including large pharmaceutical companies and generic drug manufacturers. Indivior will need to continue to innovate and expand its product pipeline in order to maintain its leadership position in the addiction treatment market.

The mental health market is also expected to grow in the coming years, driven by the increasing prevalence of mental health disorders such as schizophrenia and depression. Indivior is a relatively new entrant to this market, but the company has a number of promising products in development. Indivior will need to execute well on the commercialization of these products in order to gain market share in the competitive mental health market. Indivior is also facing increasing competition from generic drug manufacturers, which is putting pressure on the company's margins.

Overall, Indivior is a well-positioned company in the growing addiction treatment and mental health markets. The company has a strong product portfolio, a leading market position in the addiction treatment market, and a growing presence in the mental health market. However, Indivior faces competition from a number of other players in the market, and the company will need to continue to innovate and execute well in order to maintain its leadership position.

Indivior PLC Ordinary Shares: Future Outlook

Indivior PLC (INDV) is a global pharmaceutical company specializing in the treatment of addiction and mental health disorders. The company's key asset is Suboxone, a medication used to treat opioid dependence. Indivior's Ordinary Shares have experienced fluctuations in recent years, influenced by factors such as competition, litigation, and regulatory changes.

Analysts remain cautiously optimistic about INDV's future prospects. The company's focus on addiction treatment is expected to benefit from increasing demand and government initiatives. Indivior's pipeline of potential new products also provides opportunities for future growth. However, competition from generic versions of Suboxone and potential adverse legal outcomes could pose challenges.

In the short term, analysts anticipate a period of consolidation for INDV. The company is expected to focus on defending its market share and managing costs. As competition intensifies, Indivior may consider strategic partnerships or acquisitions to strengthen its position. Indivior's long-term growth will depend on the success of its new product development and its ability to navigate regulatory and legal headwinds.

Overall, analysts believe that INDV Ordinary Shares have potential for growth in the long run, but investors should be aware of the uncertainties and challenges that the company faces. By closely monitoring these developments and assessing the company's execution of its strategy, investors can make informed decisions about their investment in Indivior PLC.

Indivior PLC Ordinary Shares Operating Efficiency

Indivior PLC (Indivior) is a global pharmaceutical company focused on developing and delivering medicines for addiction and other serious mental health conditions. The company's operating efficiency is a key factor in its profitability and long-term success.

Indivior's operating efficiency has improved significantly in recent years. The company has implemented a number of initiatives to reduce costs and improve margins, including rationalizing its manufacturing and supply chain operations, reducing its workforce, and renegotiating contracts with suppliers.

As a result of these initiatives, Indivior's operating income has increased and gross and operating margins have improved. The company's net income has also grown in recent years, indicating that the company is becoming more efficient at generating profits.

Looking ahead, Indivior is well-positioned to continue to improve its operating efficiency. The company has a number of new products in its pipeline, and it is also investing in new markets and therapeutic areas. These initiatives should help Indivior to maintain its growth trajectory and continue to improve its operating efficiency.

Indivior - A Dynamic Company Facing Challenges

Indivior is a global pharmaceutical company specializing in addiction treatment and mental health. Its flagship product, Suboxone, is the leading medication for opioid dependence. However, the company faces significant risks that investors should consider.

Firstly, Indivior's reliance on Suboxone poses a risk. The opioid epidemic is declining, and there is growing competition from generic alternatives. Additionally, Indivior faces ongoing legal challenges related to the marketing of Suboxone.

Moreover, Indivior has a history of financial missteps, including accounting irregularities that led to the departure of its former CEO. The company has been implementing a turnaround plan, but it remains to be seen whether this will be successful. Indivior's financial health is further imperiled by the recent suspension of its dividend.

Despite these risks, Indivior's portfolio of products and its leading position in the addiction treatment market offer potential for growth. The company is also investing in research and development to expand its product offerings. However, investors should carefully weigh the risks and potential rewards before investing in Indivior.


  1. Ashley, R. (1983), "On the usefulness of macroeconomic forecasts as inputs to forecasting models," Journal of Forecasting, 2, 211–223.
  2. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Google's Stock Price Set to Soar in the Next 3 Months. AC Investment Research Journal, 220(44).
  3. M. J. Hausknecht and P. Stone. Deep recurrent Q-learning for partially observable MDPs. CoRR, abs/1507.06527, 2015
  4. P. Artzner, F. Delbaen, J. Eber, and D. Heath. Coherent measures of risk. Journal of Mathematical Finance, 9(3):203–228, 1999
  5. White H. 1992. Artificial Neural Networks: Approximation and Learning Theory. Oxford, UK: Blackwell
  6. Bessler, D. A. S. W. Fuller (1993), "Cointegration between U.S. wheat markets," Journal of Regional Science, 33, 481–501.
  7. Alpaydin E. 2009. Introduction to Machine Learning. Cambridge, MA: MIT Press


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.